Intuitive meta-analysis backs da Vinci across 13 conditions

Intuitive (NASDAQ: ISRG) has published what it describes as the largest comparative meta-analysis of its kind, drawing on data from more than 14 million surgical procedures across 13 common benign conditions to assess outcomes for its da Vinci robotic system against laparoscopic and open surgery.

The study, published in the peer-reviewed Annals of Surgery Open, synthesised 14 years of published evidence from 32 countries, encompassing 13 randomised controlled trials, 21 prospective cohort studies, 101 database studies, and 231 retrospective cohort studies. Procedures examined spanned gynaecology, general surgery, bariatric surgery, urology, and hernia repair, including hysterectomy, cholecystectomy, and colorectal surgery.

Key findings

Against laparoscopic surgery, da Vinci procedures were associated with 54% lower odds of conversion to open surgery and 13% lower odds of requiring a blood transfusion. Hospital stays were approximately four hours shorter and return to work around two days sooner. The analysis found no statistically significant differences in complications, infections, readmissions, or 30-day mortality, though operative time averaged 24 minutes longer.

Compared with open surgery, the findings were more pronounced. Da Vinci procedures showed 69% lower odds of requiring a blood transfusion, 46% lower odds of 30-day postoperative complications, and 60% lower odds of surgical site infection. Hospital stays were approximately two days shorter and patients returned to work around five days sooner, while operative time was on average 46 minutes longer.

Thomas H. Shin, MD, PhD, a bariatric surgeon at Mass General Brigham and the study's lead author, noted that "the most appropriate approach depends on the procedure, patient, surgeon, and clinical setting," underscoring that the analysis is intended to inform rather than prescribe.

Market context

The publication arrives as the robotic-assisted surgery market faces increasing competitive pressure. Medtronic's Hugo system and Johnson and Johnson's Ottava platform are both advancing through clinical validation, while a number of specialist and university-spinout companies are developing next-generation robotic tools for specific surgical niches. Intuitive has historically held a dominant share of installed systems globally, and peer-reviewed evidence at scale is a critical tool in defending that position against new entrants.

The company noted that more than 21 million patients worldwide have undergone procedures performed with the da Vinci system, with over 3.1 million procedures completed in 2025 alone. Intuitive also referenced a complementary oncology-focused meta-analysis, covering seven cancer surgical procedures, published separately and led by researchers at Massachusetts General Hospital.

Investors and health system procurement teams will scrutinise the study's authorship closely. Researchers from Intuitive were involved in conducting the analysis, which the company disclosed alongside a note that an independent physician reviewed and approved the materials without receiving compensation. That level of disclosure is becoming standard practice for industry-sponsored evidence, though it remains a factor clinicians and payers weigh when assessing comparative data.

The study's breadth is its clearest strength: a dataset of this scale, combining real-world and randomised evidence across multiple specialties, provides a more robust foundation than single-centre or single-indication studies. The operative time trade-off, however, remains a practical constraint for high-volume surgical units operating under capacity pressure, and will likely feature in any health technology assessment submitted to NICE or comparable bodies.